Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Accenture
Covington
US Department of Justice
UBS
Mallinckrodt

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,652,776

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,652,776 protect, and when does it expire?

Patent 8,652,776 protects FANAPT and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 8,652,776
Title:Prediction of QT prolongation based on SNP genotype
Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
Inventor(s): Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Gaithersburg, MD), Mack; Kendra Tomino (Westminster, MD), Heaton; Callie Michelle (Washington, DC)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:12/675,607
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,652,776

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-005 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-006 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-007 May 6, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,652,776

PCT Information
PCT FiledSeptember 10, 2008PCT Application Number:PCT/US2008/075905
PCT Publication Date:March 19, 2009PCT Publication Number: WO2009/036100

International Family Members for US Patent 8,652,776

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2698534   Try a Free Trial
European Patent Office 2198048   Try a Free Trial
Japan 2010538617   Try a Free Trial
Japan 5653753   Try a Free Trial
World Intellectual Property Organization (WIPO) 2009036100   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Julphar
Merck
McKinsey
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.